Additionally, TIMP-1 was found to predict the therapeutic response to several therapeutic modalities such as endocrine therapy in breast cancer and anthracycline-containing chemotherapy in pancreatic ductal carcinoma [16]. This evidence concerns the gene TIMP1 and breast carcinoma.